NCT06815029View on ClinicalTrials.gov

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

October 11, 2030

Study Completion Date

October 11, 2030

Conditions
Recurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo CSF and blood sample collection

BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells intracranially

PROCEDURE

Echocardiography

Undergo echocardiography

OTHER

Fludeoxyglucose F-18

Undergo FDG-PET

PROCEDURE

Intracranial Catheter Placement

Undergo placement of Rickham catheter

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo FDG-PET

PROCEDURE

Resection

Undergo surgical resection

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER